企業プロフィール
Acumen Pharmaceuticals 株価・ニュース・カタリスト
- ティッカー:
- ABOS
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
2.66 USD (-0.37%)
終値
最終更新: 2026年8月17日
171M USD
時価総額
株価変動の要因
As of Aug 17, 2026, ABOS closed down 0.37% at $2.66. No new same-company headline was identified in the current news window.
企業概要
Alzheimer’s Disease Antibody Company
Acumen Pharmaceuticals develops therapies targeting soluble amyloid-beta oligomers, which are believed to contribute directly to synaptic dysfunction in Alzheimer’s disease.
Sabirnetug
Sabirnetug is a monoclonal antibody designed to selectively bind toxic amyloid-beta oligomers while limiting interaction with monomers and plaques.
Enhanced Brain Delivery
Acumen is also developing an enhanced brain-delivery platform intended to improve central nervous system exposure of future biologics.
今後のカタリスト
- Topline results from the Phase 2 ALTITUDE-AD study of sabirnetug are expected in late 2026.
- An IND filing for the lead enhanced brain-delivery candidate is targeted for mid-2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。